Adaptive Biotechnologies Officer & Director Files Intent to Sell $6.8M in Stock
ADPT sits 100% above its 52-week low of $6.675.
Summary
An Officer and Director of Adaptive Biotechnologies has filed a Form 144 to sell approximately $6.8 million worth of stock, continuing a pattern of significant insider selling.
Key Events · Ownership and Investor Activity · ADPT
-
Officer & Director Files Intent to Sell
Chad M. Robins, an Officer and Director, filed a Form 144 to sell 470,167 shares of common stock, valued at approximately $6.8 million.
-
Follows Recent Vesting
The shares intended for sale were acquired upon the vesting of restricted stock units and performance stock units on March 4, 2026.
-
Part of Ongoing Insider Distribution
This proposed sale adds to a pattern of significant insider selling by Robins, who has already sold over $12.5 million in shares in the past three months. The company has seen over $32 million in net insider selling across all insiders in the last 90 days.
Analysis · ADPT · Life Sciences
Chad M. Robins, an Officer and Director of Adaptive Biotechnologies, has filed a Form 144 indicating an intent to sell 470,167 shares of common stock, valued at approximately $6.8 million. This proposed sale follows the recent vesting of restricted stock units and performance stock units. This transaction is part of a broader pattern of significant insider distribution, with Robins having sold over $12.5 million in shares in the past three months, contributing to a total net insider selling of over $32 million across the company in the last 90 days. While often related to liquidity or tax planning, a substantial and ongoing selling trend by a key executive can be perceived negatively by investors, especially following the company's recent positive financial results.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADPT was trading at $13.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.68 to $20.76. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.